First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

Gatzemeier, U.; Pawel, Joachim von; Vynnychenko, I.; Zatloukal, Petr; Marinis, Filippo de; Eberhardt, Wilfried; Paz‐Ares, Luis; Schumacher, Karl; Goddemeier, Thomas; O’Byrne, Kenneth J.; Pirker, Robert

doi:10.1016/s1470-2045(10)70278-3

Cited by 104 publications

(66 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the randomized phase III studies the activity seemed consistent regardless of EGFR FISH status [5,43]. So far the most promising biomarker seems to be presence of skin rash as supported by the observations in the FLEX trial [44] but cannot yet be considered a tool for patient selection. However, high EGFR expression might be a promising predictive biomarker for cetuximab therapy in the future as shown by a new data analysis from the FLEX trial [45].…”

Section: Discussionmentioning

confidence: 97%

Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb

Fischer

Griesinger

Fink³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb

Fischer

Griesinger

Fink³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

“…Patients in the chemotherapy plus cetuximab group with first-cycle rash had significantly prolonged OS compared with patients in the same treatment group without first-cycle rash (median 15.0 months vs 8.8 months; P , 0.0001). 46 OS for patients without first-cycle rash was similar to that of patients who received chemotherapy alone (median 8.8 months vs 10.3 months; P = 0.36). Rash may therefore be a surrogate marker of target inhibition and activity of cetuximab-based chemotherapies.…”

Section: Clinical Predictors Of Responsementioning

confidence: 69%

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

Takeda¹,

Okamoto²,

Nishimura³

et al. 2011

LCTT

View full text Add to dashboard Cite

Abstract:The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EGFR, have been developed. Such monoclonal antibodies have shown efficacy in combination with chemotherapy and radiotherapy. Nimotuzumab (h-R3) is a humanized monoclonal antibody to EGFR, and its effects in combination with radiation have been sufficiently promising to warrant further investigation in several types of cancer. Furthermore, the typical severe dermatologic toxicities associated with other monoclonal antibodies to EGFR have not been observed with nimotuzumab. We here summarize the results of preclinical studies as well as of previous and ongoing clinical trials of nimotuzumab for the treatment of non-small cell lung cancer.

show abstract

“…The correlation of adverse-events with response to treatment has been reported in a few other situations, skin rash for antibodies directed at the EGFR 23) or tyrosine-kinase inhibitors 15) . In addition, women reporting either joint or vasomotor symptoms had a significant decrease in recurrence compared with those reporting neither symptom in adjuvant endocrine therapy 13) .…”

Section: Discussionmentioning

confidence: 87%

S-1-associated hand-foot syndrome as a prognostic factor in patients with metastatic breast cancer

Hirano

Hattori

Inoue

et al. 2015

Ann. Cancer Res. Therap.

View full text Add to dashboard Cite

Purpose: S-1, an orally administered fluorinated pyrimidine (FP), is reported to be effective for the treatment of metastatic breast cancer (MBC). Although capecitabine, another oral FP, is widely accepted as the third-line chemotherapy for MBC, many patients treated with capecitabine suffer from hand-foot syndrome (HFS). HFS also affects survival in patients with metastatic colorectal and breast cancer. We retrospectively evaluated the potential association of HFS and survival in patients with MBC receiving S-1. Methods: Forty-four patients with MBC treated with S-1 between 2005 and 2012 were analyzed. S-1 was administered at a standard dose of 50 mg/body twice daily for 4 weeks, followed by a 2-week interval. Partly, the drug was administered for 2 weeks, followed by a one-week interval. Trastuzumab (2 mg/kg/week) was added to the regimen for HER2-positive patients. Results:The median follow-up period was 25.8 months and 12 patients (27.3%) developed HFS. Grade (G) 1 HFS was observed in 9 patients (20.5%) and G2 in 3 patients (6.8%). No G3/4 HFS was observed. Baseline demographic characteristics were comparable between the HFS and non-HFS patient groups. The HFS group showed a superior response rate (50.0% vs. 9.4%; P=0.0046), and improved median PFS (9.8 vs. 4.7 months; log-rank P=0.0446) and OS (51.5 vs. 17.5 months; logrank P=0.0196). In multivariate analysis, HFS is the only and independent prognostic factor (HR 2.93; 95% CI, 1.12 to 9.27; P=0.0269) of OS. Conclusion: HFS observed in patients with S-1 not only correlates with an antitumor effect, but is also an independent prognostic factor.

show abstract

First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study

Cited by 104 publications

References 27 publications

Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb

Docetaxel–carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)—Results of the nonrandomised phase II study TaxErb

Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer

S-1-associated hand-foot syndrome as a prognostic factor in patients with metastatic breast cancer

Contact Info

Product

Resources

About